CEA test is much more useful in detecting prognosis other than early diagnostic phase, thus exponential growth is expected in Global CEA Market
According to a recently published report, the Global Carcinoembryonic Antigen (CEA) Market is expected to grow at the CAGR of 6.3% during 2017-2025. The global carcinoembryonic antigen (CEA) market is segmented on the basis of application, and geography. The report on global carcinoembryonic antigen (CEA) market forecast 2017-2025 (by application, and geography) provides a detailed overview and predictive analysis of the market.
Full report available Global Carcinoembryonic antigen (CEA) Market 2017 – 2025 (by application, and geography) report at http://www.briskinsights.com/report/carcinoembryonic-antigen-cea-market
Carcinoembryonic antigen (CEA) is known as an oncofetal glycoprotein available in the gastrointestinal tract and body fluids of the embryo and fetus. CEA is also present in certain adult gastrointestinal cells, including the mucosal cells of the colon, and in minute amounts in the blood. Market experts suggested that, major growth drivers aiding the growth of CEA market comprises rising prevalence of cancer, significant growth in the global population base, and increasing demand for minimally invasive diagnostic procedures in cancer. Other factors that assist the overall global market growth are high healthcare expenditure which is fueling the demand for effective diagnostic technologies for oncology and promoting the application of combination biomarkers in oncology treatment.
On the basis of application the global carcinoembryonic antigen (CEA) market is segmented into colorectal cancer, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, thyroid cancer and other cancers. In year 2016, colorectal cancer was observed as the largest CEA market in terms of revenue due to key drivers responsible for its growth are rise in alcohol consumption in young population, sedentary lifestyle, and high intake of saturated fats in all age groups. In addition to this, growing preference for CEA tests in cancer diagnosis and management is anticipated to aid its market growth in the near future.
North America was observed as the largest CEA market in year 2016 due to growing demand for minimally invasive cancer diagnosis tests, high public awareness related to early cancer diagnosis, and high accessibility for advanced health care facilities for cancer management. The market experts also suggested that, technological advancements followed by novel discoveries of specific antigens and biomarkers are expected to fuel the growth of CEA market testing in this region. Asia-Pacific was market was observed as the fastest growing market during the forecast period 2016 – 2025 due to key market driving factors such as aging population, rising demand and acceptance for technologically advanced healthcare facilities, supportive governmental policies, and high demand for cost effective and precise diagnostic procedures.
Scope of the report
1. Global Carcinoembryonic Antigen (CEA) Market, By Application Type, 2015–2025 ($ Millon)
1.1. Ovarian cancer
1.2. Colorectal Cancer
1.3. Pancreatic Cancer
1.4. Lung Cancer
1.5. Breast Cancer
1.6. Thyroid Cancer
1.7. Other Cancers
2. Global Carcinoembryonic Antigen (CEA) Market, By Geography, 2015-2025 ($ Millon)
2.1. North America
2.3. Asia Pacific
2.4. Latin America (LATAM)
2.5. Middle East and Africa (MEA)
3. Company Profiles
3.1. Abbott Laboratories
3.2. Quest Diagnostics
3.3. F. Hoffman LA Roche
3.4. GenWay Biotech Inc.
3.5. Correlogic Systems, Inc.